Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics MS Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Healthcare Administered Multiple Sclerosis Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity limits for healthcare-administered multiple sclerosis therapies under the Boeing commercial formulary. It applies to providers requesting Lemtrada, Ocrevus, Ocrevus Zunovo, Tyruko, or Tysabri for eligible members.

    Policy Summary
    PayerPrime Therapeutics
    PolicyHealthcare Administered Multiple Sclerosis Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with all applicable clinical criteria and supporting documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Target multiple sclerosis agents
    12 monthsInitial authorization
    12 monthsRenewal authorization
    5 vials/yearLemtrada limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 vial/28 daysTysabri limit
    3Alternative DMTs

    Coverage Criteria

    Initial Therapy

    Target Agent(s) will be approved when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • A. Continuation of therapy

        • The requested agent is eligible for continuation of therapy.
        • The prescriber states that the patient has been treated with the requested agent within the past 90 days and is at risk if therapy is changed.
      • B. Initial therapy

        • ALL of the following

          • The patient has a diagnosis of one of the following relapsing forms of multiple sclerosis (MS): relapsing-remitting disease (RRMS) or active secondary progressive disease (SPMS).
          • ONE of the following

            • ALL of the following

              • The patient has highly active MS disease activity.
              • ONE of the following

                • Greater than or equal to 2 relapses in the previous year.
                • ANY of the following

                  • Greater than or equal to 1 gadolinium-enhancing lesion on MRI.
                  • A significant increase in T2 lesion load compared with a previous MRI.
            • The patient has been treated with 3 disease-modifying therapies (DMTs) from different drug classes.
          • The patient has another FDA-labeled indication for the requested agent and route of administration.
          • The patient has an indication supported in compendia for the requested agent and route of administration.
        • If the patient has an FDA-labeled indication, ONE of the following

          • The patient's age is within FDA labeling for the requested indication for the requested agent.
          • There is support for using the requested agent for the patient's age for the requested indication.
      • The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
      • The patient will NOT be using the requested agent in combination with another disease-modifying therapy (DMT) per the Disease Modifying Therapies list.
      • The patient does NOT have any FDA-labeled contraindications to the requested agent.
      • If the patient has been previously treated with the requested agent, the patient has NOT received a prior course with the requested agent within the past 12 months.

    Continuation Therapy

    Target Agent(s) will be approved when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient has NOT received a prior course with the requested agent within the past 12 months.
    • The patient will NOT be using the requested agent in combination with another disease-modifying therapy (DMT) per the Disease Modifying Therapies list.

    Initial Therapy — Continuation Eligibility or Alternative Clinical Pathway

    Target Agent(s) will be approved when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • A. Continuation of therapy

        • The requested agent is eligible for continuation of therapy.
        • The prescriber states that the patient has been treated with the requested agent within the past 210 days and is at risk if therapy is changed.
      • B. Alternative clinical pathway

        • ONE of the following

          • The patient has a diagnosis of a relapsing form of multiple sclerosis (MS).

    Continuation and Renewal Therapy

    Target Agent(s) will be approved when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • The patient has had clinical benefit from treatment with the requested agent.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient will NOT be using the requested agent in combination with another disease-modifying therapy (DMT) per the Disease Modifying Therapies list.
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Quantity-Limit Approval Criteria

    Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met:

    ONE of the following

    • The requested quantity (dose) does NOT exceed the program quantity limit.
    • ALL of the following

      • The requested quantity (dose) exceeds the program quantity limit.
      • ONE of the following

        • ALL of the following

          • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.

    Coverage is excluded when the requested agent will be used in combination with another disease-modifying therapy (DMT) listed in the Disease Modifying Therapies list.

    Coverage is excluded when the patient has an FDA-labeled contraindication to the requested agent.

    Coverage is excluded if the patient received a prior course of the requested agent within the past 12 months.

    Continuation or renewal coverage is excluded when the requested agent will be used in combination with another disease-modifying therapy (DMT) listed in the Disease Modifying Therapies list.

    Continuation or renewal coverage is excluded when the patient has an FDA-labeled contraindication to the requested agent.

    Concomitant use of multiple sclerosis disease-modifying therapies with listed immunomodulatory agents is contraindicated. Listed agents include Abrilada (adalimumab-afzb), Actemra (tocilizumab), Adalimumab, Adbry (tralokinumab-ldrm), Amjevita (adalimumab-atto), Anzupgo (delgocitinib), Arcalyst (rilonacept), Avsola (infliximab-axxq), Avtozma (tocilizumab-anoh), Tysabri (natalizumab), Ustekinumab, Velsipity (etrasimod), Wezlana (ustekinumab-auub), Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended release), Xolair (omalizumab), Yesintek (ustekinumab-kfce), Yuflyma (adalimumab-aaty), Yusimry (adalimumab-aqvh), and Zeposia (ozanimod).

    Concomitant therapy involving the listed contraindicated immunomodulatory agents is excluded. The list includes Ustekinumab, Velsipity (etrasimod), Wezlana (ustekinumab-auub), Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended release), Xolair (omalizumab), Yesintek (ustekinumab-kfce), Yuflyma (adalimumab-aaty), Yusimry (adalimumab-aqvh), and Zeposia (ozanimod).

    The listed immunomodulatory agents must not be used concomitantly with the requested multiple sclerosis disease-modifying therapy.

    Clinical Coding and Thresholds

    Relapse activity threshold
    Relapse thresholdAt least 2 relapses in the previous year
    Disease contextHighly active multiple sclerosis disease activity
    Qualifying pathwayRelapsing-remitting disease or active secondary progressive disease with qualifying activity
    MRI disease activity threshold
    Gadolinium-enhancing lesionAt least 1 lesion on MRI
    T2 lesion loadSignificant increase compared with a previous MRI
    Qualifying useEither MRI finding may support highly active multiple sclerosis disease activity

    Provider Submission and Decision Guidance

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required before initiating a covered healthcare-administered target agent for multiple sclerosis. Submit the request for initial clinical review and include the applicable diagnosis, treatment history, and agent-specific clinical information.

    • Applies to target healthcare-administered multiple sclerosis agents, including agents evaluated under the initial-therapy criteria.
    Prior Authorization

    Renewal Prior Authorization

    Renewal prior authorization is required for continued treatment. Renewal requests must establish prior plan approval, clinical benefit, specialist involvement or consultation, and continued satisfaction of the safety and concomitant-therapy requirements.

    • Patients without prior approval require initial evaluation review.
    • The patient must not have received a prior course with the requested agent within the past 12 months.
    • The patient must not use the requested agent with another disease-modifying therapy (DMT) and must not have an FDA-labeled contraindication.

    Policy Background

    This policy addresses disease-modifying therapies for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis. Initial coverage may depend on disease activity, MRI findings, prior disease-modifying therapy, or an applicable preferred-agent exception pathway.

    Definitions

    Relapsing multiple sclerosis forms
    Relapsing-remitting MSRelapsing-remitting disease (RRMS)
    Active secondary progressive MSActive secondary progressive disease (SPMS)
    Policy useThese are the relapsing forms of multiple sclerosis identified for the clinical pathway
    Highly active multiple sclerosis disease activity
    Relapse findingAt least 2 relapses in the previous year
    MRI lesion findingAt least 1 gadolinium-enhancing lesion on MRI
    MRI lesion-load finding

    Initial Therapy Criteria

    Initial Authorization Criteria

    Initial approval requires all common requirements and one qualifying indication and disease or treatment pathway.

    Initial authorization: The patient has a qualifying indication; the indication is FDA-labeled or supported in compendia for the requested agent and route; applicable age requirements are satisfied; the prescriber is a specialist in the diagnosis or has consulted with a specialist; the requested agent will not be used with another disease-modifying therapy; the patient has no FDA-labeled contraindication to the requested agent; and the patient has not received a prior course of the requested agent within the past 12 months.

    Qualifying indication and disease or treatment pathway

    • Disease activity: The patient has at least 2 relapses in the previous year, at least 1 gadolinium-enhancing lesion on MRI, or a significant increase in T2 lesion load compared with a previous MRI.
    • Prior treatment or preferred-agent exception:

    Continuation and Renewal Criteria

    Renewal of Therapy Criteria

    Renewal approval requires all listed criteria.

    Continuation criteria: The patient was previously approved for the requested agent through the plan's prior authorization process; clinical benefit has been demonstrated; the prescriber is a specialist in the area of the patient's diagnosis or has consulted with a specialist; the patient has not received a prior course with the requested agent within the past 12 months; the requested agent will not be used in combination with another disease-modifying therapy; and the patient has no FDA-labeled contraindication to the requested agent.

    Patients not previously approved require initial evaluation review.

    Continuation Eligibility Criteria

    The requested agent must be eligible for continuation therapy.

    Eligible continuation therapy: The requested agent is eligible for continuation therapy, and the prescriber states that the patient has been treated with the requested agent within the past 210 days and is at risk if therapy is changed.Past 210 days

    Step Therapy Pathways

    PathwayRequirementWhen pathway is satisfied
    Preferred-agent step therapyUse or address applicable preferred multiple sclerosis disease-modifying agents before the requested non-preferred healthcare-administered agent. Preferred agents include Avonex, Betaseron, dimethyl fumarate, fingolimod, glatiramer, Glatopa, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, teriflunomide, Vumerity, and Zeposia.The patient has tried and had an inadequate response to two preferred agents FDA-labeled for the requested indication.
    Preferred-agent exceptionAn exception may apply for intolerance or hypersensitivity to one or two preferred agents, an FDA-labeled contraindication to all applicable preferred agents, or support for using the requested agent over all applicable preferred agents.The applicable exception is documented; chart notes are required for the documented exception pathway.
    Alternative pathwayRequirementQualification
    Three prior DMT classesThe patient has been treated with three disease-modifying therapies from different drug classes.This treatment history may satisfy the alternative initial-therapy pathway.

    Agent-Specific Quantity Limits

    Lemtrada quantity limit
    Quantity limit5 vials
    Time period365 days
    AgentLemtrada (alemtuzumab)
    Ocrevus quantity limit
    Quantity limitNot specified in the source summary
    Time period180 days
    Dose formVials
    Policy Summary
    PayerPrime Therapeutics
    PolicyHealthcare Administered Multiple Sclerosis Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with all applicable clinical criteria and supporting documentation.
    SourceLink
    On This Page
    Coverage CriteriaClinical Coding and ThresholdsProvider Submission and Decision GuidancePolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation and Renewal CriteriaStep Therapy PathwaysAgent-Specific Quantity Limits
  1. ONE of the following [chart notes required]

    • The patient has tried and had an inadequate response to TWO preferred agents FDA labeled for the requested indication.
    • The patient has tried and had an inadequate response to ONE preferred agent FDA labeled for the requested indication and has an intolerance or hypersensitivity to ONE preferred agent FDA labeled for the requested indication.
    • The patient has an intolerance or hypersensitivity to TWO preferred agents FDA labeled for the requested indication.
    • The patient has an FDA-labeled contraindication to ALL preferred agents FDA labeled for the requested indication.
    • There is support for using the requested agent over ALL preferred agents FDA labeled for the requested indication.
  2. The patient does NOT have any FDA-labeled contraindications to the requested agent.
  3. The patient has a diagnosis of primary progressive multiple sclerosis (PPMS).
  4. The patient has another FDA-labeled indication for the requested agent and route of administration.
  5. If the patient has an FDA-labeled indication, ONE of the following

    • The patient's age is within FDA labeling for the requested indication for the requested agent.
    • There is support for using the requested agent for the patient's age for the requested indication.
  6. The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
  7. The patient will NOT be using the requested agent in combination with another disease-modifying therapy (DMT) per the Disease Modifying Therapies list.
  8. The patient does NOT have any FDA-labeled contraindications to the requested agent.
  9. There is support for therapy with a higher dose for the requested indication.
  10. ALL of the following

    • The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication.
    • There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit.
  11. Prior disease-modifying therapy classes
    Prior-treatment thresholdTreatment with 3 disease-modifying therapies
    Class requirementThe 3 therapies must be from different drug classes
    Authorization pathwayMay satisfy the alternative initial-therapy treatment-history pathway
    Prior Authorization

    Initial Authorization Pathways

    For initial authorization, document either qualifying continuation eligibility or an applicable initial-therapy pathway. Continuation eligibility requires treatment with the requested agent within the past 90 days and a statement that changing therapy places the patient at risk.

    • Alternative initial pathways may be based on a relapsing MS diagnosis with qualifying disease activity, treatment with three DMTs from different drug classes, preferred-agent failure or intolerance, contraindication to preferred agents, or support for use over all preferred agents.
    • The requested agent may also qualify for another FDA-labeled indication or a compendia-supported indication for the requested route of administration.
    Prior Authorization

    Renewal Eligibility and Clinical Benefit

    Renewal authorization requires prior approval through the plan's prior authorization process and evidence of clinical benefit from the requested agent. The prescriber must be a specialist in the diagnosis area or have consulted with one.

    • The patient must not use the requested agent with another DMT.
    • The patient must not have an FDA-labeled contraindication to the requested agent.
    Prior Authorization

    Quantity Limit Exceeded

    A quantity-limit prior authorization or exception is required when the requested dose exceeds the program quantity limit. Submit clinical justification for the excess quantity under one of the policy's exception pathways.

    • The quantity may exceed the limit when there is no maximum FDA-labeled dose for the indication and higher-dose therapy is supported.
    • Alternatively, the dose must not exceed the maximum FDA-labeled dose and the provider must explain why it cannot be achieved with a lower quantity of a higher strength that remains within the limit.
    Note

    Approval Duration and Loading Doses

    Approvals are generally issued for 12 months. For a new start requiring a loading dose, approve the loading dose according to FDA labeling, followed by the maintenance dose for the remainder of the approval period.

    • Refer to the quantity-limit criteria when a quantity limit applies.
    Step Therapy

    Preferred-Agent Alternatives

    Preferred-agent alternatives include Avonex, Betaseron, dimethyl fumarate, fingolimod, glatiramer, Glatopa, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, teriflunomide, Vumerity, and Zeposia. Non-preferred alternatives include Aubagio, Bafiertam, Copaxone, Extavia, Gilenya, Ponvory, Tascenso ODT, and Tecfidera.

    • For the applicable requested indication, document that the patient tried and had an inadequate response to two preferred agents, or has the required intolerance, hypersensitivity, contraindication, or clinical rationale supporting use of the requested agent over all preferred agents.
    • Use the preferred-agent pathway when it applies before requesting a non-preferred agent.
    Step Therapy

    Three-Class DMT History

    An alternative initial-therapy pathway is available when the patient has been treated with three DMTs from different drug classes, as defined by the policy's Drug Classes table.

    • Document each prior DMT, its drug class, treatment dates or duration, and the outcome of therapy.
    Documentation Required

    Chart Notes for Exception Pathways

    Submit chart notes for exception pathways. Chart notes must support preferred-agent failure, inadequate response, intolerance, hypersensitivity, contraindication, or the rationale for using the requested agent over all preferred agents.

    • Include the relevant diagnosis, prior therapies, response or adverse effects, and clinical rationale.
    • Chart notes are required when relying on the exception or preferred-agent pathway.
    Documentation Required

    Clinical Records Supporting Initial Review

    Submit clinical records supporting the initial review, including the diagnosis, disease activity, treatment history, indication, age-related rationale when applicable, prescriber specialty or specialist consultation, and safety review.

    • For relapsing MS, document relapsing-remitting disease or active secondary progressive disease and qualifying disease activity, such as at least two relapses in the previous year or qualifying MRI findings.
    • Document any other FDA-labeled or compendia-supported indication and the route of administration.
    Documentation Required

    Renewal Documentation

    Renewal submissions must include documentation of prior approval, continued treatment, clinical benefit, prescriber specialty or specialist consultation, and the absence of prohibited concomitant therapy or FDA-labeled contraindications.

    • Document that the patient has not received a prior course with the requested agent within the past 12 months.
    • Document that the requested agent will not be used with another DMT.
    Documentation Required

    Clinical and Prescriber Documentation

    For initial therapy, submit clinical and prescriber documentation showing the diagnosis and qualifying indication, age appropriateness or age-specific clinical support, specialist involvement, and required treatment history.

    • The prescriber must be a specialist in the diagnosis area, such as a neurologist, or must have consulted with one.
    • Document that the requested agent will not be used with another DMT and that no FDA-labeled contraindication applies.
    Documentation Required

    Continuation Documentation

    For continuation eligibility, document that the patient has been treated with the requested agent within the past 210 days and is at risk if therapy is changed.

    • Continuation agents include Tyruko, Tysabri, Ocrevus, and Ocrevus Zunovo.
    • If continuation criteria are not met, submit the applicable initial-therapy documentation instead.
    Documentation Required

    Renewal Prior Approval and Benefit

    Renewal documentation must establish that the requested agent was previously approved through the plan's prior authorization process and that the patient has experienced clinical benefit from treatment.

    • Include the prescriber's specialist status or consultation documentation.
    • Confirm no concomitant DMT use and no FDA-labeled contraindication.
    Documentation Required

    Quantity-Limit Exception Documentation

    For a quantity-limit exception, submit documentation supporting the requested excess dose under a permitted exception pathway.

    • Document that no maximum FDA-labeled dose applies and provide support for higher-dose therapy, or document that the requested dose is within the maximum FDA-labeled dose and explain why a lower quantity of a higher strength cannot be used.
    • The quantity-limit exception must be clinically supported and specific to the requested indication and dose.
    Denial Risk

    Denial Risk: Clinical or Safety Criteria

    Requests may be denied when the clinical or safety criteria are not met, including failure to demonstrate a qualifying indication, required treatment history, appropriate age rationale, specialist involvement, or acceptable concomitant-therapy and contraindication status.

    • Failure to provide required chart notes or clinical support may prevent approval.
    • The requested agent must not be used with another DMT and must not have an FDA-labeled contraindication.
    Denial Risk

    Denial Risk: Indication or Treatment History

    A request may be denied when the patient lacks a qualifying FDA-labeled or compendia-supported indication, does not meet the required MS disease-activity or treatment-history pathway, or lacks support for use over preferred agents.

    • For applicable relapsing MS pathways, document RRMS or active SPMS and qualifying disease activity.
    • The three-DMT pathway requires treatment with DMTs from three different drug classes.
    • Preferred-agent exceptions require documentation of inadequate response, intolerance, hypersensitivity, contraindication, or clinical rationale.
    Denial Risk

    Denial Risk: Quantity Limit Exceeded

    The request may be denied when the prescribed dose or quantity exceeds the applicable program quantity limit and the provider does not establish a qualifying exception.

    • Quantity limits vary by agent; examples include Lemtrada: 5 vials per 365 days and Tysabri: 1 vial per 28 days.
    • Submit the required higher-dose or alternate-strength justification for an exception.
    Denial Risk

    Denial Risk: Concomitant DMT or Contraindication

    Authorization may be denied when the requested agent is used concomitantly with another DMT or when an FDA-labeled contraindication applies to the requested agent.

    • Review the patient's complete medication list before submission.
    • Do not combine the requested agent with another disease-modifying therapy.
    Denial Risk

    Denial Risk: Renewal Eligibility

    Renewal may be denied when prior plan approval is not established, continued clinical benefit is not demonstrated, specialist involvement is not documented, or renewal safety requirements are not met.

    • Patients without prior approval require initial evaluation review.
    • The patient must not use the requested agent with another DMT or have an FDA-labeled contraindication.
    Denial Risk

    Denial Risk: Unsupported Quantity Exception

    A quantity-limit exception may be denied when the request lacks clinical support for the excess quantity, exceeds the maximum FDA-labeled dose, or could be achieved with a lower quantity of a higher strength within the program limit.

    • Provide dose-specific documentation for the requested indication.
    • Approval is limited to the quantity supported by the applicable exception criteria.
    Denial Risk

    Avoid Contraindicated Concomitant Therapy

    Do not use the requested MS DMT concomitantly with another DMT or with listed immunomodulatory agents identified by the policy as contraindicated concomitant therapy.

    • Listed immunomodulatory agents include, among others, Abrilada, Actemra, adalimumab products, Adbry, Amjevita, Arcalyst, Avsola, Avtozma, Ustekinumab products, Velsipity, Wezlana, Xeljanz, Xeljanz XR, Xolair, and Yesintek.
    • Tysabri is identified in the policy's contraindicated-concomitant-therapy listings.
    Documentation Required

    Medication-List Review Required

    Review the full medication list and avoid combining the requested MS agent with any listed immunomodulatory agent identified as contraindicated concomitant therapy.

    • The policy listings include ustekinumab products, Velsipity, Wezlana, Xeljanz, Xeljanz XR, Xolair, Yesintek, Yuflyma, and Yusimry, among other listed agents.
    • Zeposia and other listed MS therapies may also appear in the contraindicated-concomitant-therapy listings; verify the complete current policy list.
    Denial Risk

    Concomitant Therapy Can Cause Nonapproval

    Contraindicated concomitant therapy may trigger denial or nonapproval. Confirm that the requested agent is not being administered with another DMT or a listed immunomodulatory agent before submitting the request.

    • Document medication reconciliation when relevant to the review.
    • Examples in the policy listings include Velsipity, Wezlana, Xeljanz, Xeljanz XR, Xolair, Yesintek, Yuflyma, Yusimry, and Zeposia.
    Significant increase in T2 lesion load compared with a previous MRI
    Disease-modifying therapy
    DefinitionTherapies included on the policy's Disease Modifying Therapies list
    Combination restrictionThe requested agent must not be used in combination with another listed disease-modifying therapy
    Clinical roleDisease-modifying therapies may support the treatment-history pathway when used from different drug classes
    Multiple sclerosis disease-modifying therapies and classes
    CD20 monoclonal antibodyBriumvi, Kesimpta, Ocrevus, and Ocrevus Zunovo
    CD52 monoclonal antibodyLemtrada
    FumarateBafiertam, Tecfidera, and Vumerity
    GlatiramerCopaxone and Glatopa
    Integrin inhibitor (Anti-VLA-4)Tyruko and Tysabri
    InterferonAvonex, Betaseron, Extavia, Plegridy, and Rebif
    Other listed classesPurine antimetabolite; pyrimidine synthesis inhibitor; and sphingosine 1-phosphate (SIP) receptor modulator
    Concomitant therapy
    MeaningSimultaneous use of two or more agents
    Covered agent groupAgents from the listed immunomodulatory-agent group
    Policy statusConcomitant use identified in the policy is contraindicated
    The patient has been treated with 3 disease-modifying therapies from different drug classes, or has tried and had an inadequate response to 2 preferred agents, has applicable intolerance or hypersensitivity, has an FDA-labeled contraindication to all applicable preferred agents, or there is support for using the requested agent over all applicable preferred agents.

    Chart notes are required for preferred-agent exception pathways.

  12. Other qualifying indication: The patient has another FDA-labeled indication or an indication supported in compendia for the requested agent and route of administration.
  13. Initial MS Therapy Criteria

    Initial therapy is approved when all applicable clinical, prescriber, combination-therapy, and safety requirements are met.

    Initial MS therapy requirements: The patient has a qualifying multiple sclerosis diagnosis or another FDA-labeled indication; applicable age requirements are satisfied; the prescriber is a specialist in the area of the patient's diagnosis or has consulted with a specialist; the patient will not use the requested agent with another disease-modifying therapy; and the patient has no FDA-labeled contraindication to the requested agent.

    Qualifying multiple sclerosis diagnoses include relapsing multiple sclerosis and primary progressive multiple sclerosis.

    Eligible agents include Tyruko, Tysabri, Ocrevus, and Ocrevus Zunovo.

    Ocrevus Zunovo quantity limit
    Quantity limitNot specified in the source summary
    Time period180 days
    Dose formVial
    Tyruko quantity limit
    Quantity limitNot specified in the source summary
    Time period28 days
    Dose formVial
    Tysabri quantity limit
    Quantity limit1 vial
    Time period28 days
    AgentTysabri (natalizumab)
    Quantity-limit approval criterion
    Standard approvalRequested dose does not exceed the program quantity limit
    No maximum FDA-labeled dose pathwayThe requested indication has no maximum FDA-labeled dose and support is provided for therapy with a higher dose
    Higher-strength pathwayThe dose is within the maximum FDA-labeled dose and support explains why it cannot be achieved with a lower quantity of a higher strength within the limit
    Agents covered by the quantity-limit program and exception rule
    Covered agentsLemtrada, Ocrevus, Ocrevus Zunovo, Tyruko, and Tysabri
    Within-limit ruleThe requested quantity must not exceed the applicable program quantity limit
    Exception ruleAn amount above the limit requires support under the no-maximum-dose or higher-strength pathway